# Dianthus Therapeutics, Inc.: overview DNTH · Nasdaq · CIK 1690585 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/dnth.md) · [Financials](/companies/dnth/financials.md) · [Filings](/companies/dnth/filings.md) · [Insiders](/companies/dnth/insiders.md) Latest reported revenue: [$284.0k](/filings/0001690585-26-000006.md) for Q4 FY2025, three months to 2025-12-31, from the 10-K filed Mar 9, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001690585-26-000006). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [2,172](/filings/0001193125-25-266920.md) | [1,326 d](/filings/0001690585-26-000006.md) | [1,163](/filings/0000950170-25-069226.md) | [193](/filings/0000950170-25-105030.md) | [396](/filings/0001193125-25-266920.md) | [284 d](/filings/0001690585-26-000006.md) | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(1376.6%)](/filings/0001193125-25-266920.md) | [(2406.9%) d](/filings/0001690585-26-000006.md) | [(2852.7%)](/filings/0001690585-26-000022.md) | [(18096.9%)](/filings/0001690585-26-000034.md) | [(10173.7%)](/filings/0001193125-25-266920.md) | [(24486.3%) d](/filings/0001690585-26-000006.md) | not reported | not reported | | Net margin | % | [(1159.0%)](/filings/0001193125-25-266920.md) | [(2144.8%) d](/filings/0001690585-26-000006.md) | [(2537.5%)](/filings/0001690585-26-000034.md) | [(16388.1%)](/filings/0001690585-26-000034.md) | [(9284.1%)](/filings/0001193125-25-266920.md) | [(22687.3%) d](/filings/0001690585-26-000006.md) | not reported | not reported | | Diluted EPS | $ per share | [(0.74)](/filings/0001193125-25-266920.md) | not reported | [(0.82)](/filings/0001690585-26-000022.md) | [(0.88)](/filings/0001690585-26-000034.md) | [(0.97)](/filings/0001193125-25-266920.md) | not reported | [(0.85)](/filings/0001690585-26-000022.md) | [(0.90)](/filings/0001690585-26-000034.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | [2.8](/filings/0000950170-25-037131.md) | [6.2](/filings/0001690585-26-000006.md) | [2.0](/filings/0001690585-26-000006.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | [(1704.7%)](/filings/0000950170-25-037131.md) | [(1633.7%)](/filings/0001690585-26-000006.md) | [(8739.3%)](/filings/0001690585-26-000006.md) | | Net margin | % | not reported | not reported | [(1541.2%)](/filings/0000950170-25-037131.md) | [(1362.8%)](/filings/0001690585-26-000006.md) | [(7973.3%)](/filings/0001690585-26-000006.md) | | Diluted EPS | $ per share | [(1.29)](/filings/0000950170-23-009331.md) | [(32.57)](/filings/0000950170-24-034681.md) | [(8.45)](/filings/0000950170-25-037131.md) | [(2.55)](/filings/0001690585-26-000006.md) | [(4.20)](/filings/0001690585-26-000006.md) | | Free cash flow | $m | [(60.8)](/filings/0000950170-23-009331.md) | [(29.4)](/filings/0000950170-24-034681.md) | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/dnth/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $799.3m | 8,199,893 | | Added +432,207 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $402.0m | 4,123,822 | | Added +948,119 | | [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $314.8m | 3,229,882 | | Added +634,099 | | [Fairmount Funds Management LLC](/funds/1802528.md) | 2026-06-30 | $247.3m | 2,537,191 | | Unchanged | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $229.8m | 2,357,440 | | Added +958,527 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $210.5m | 2,159,568 | | Added +128,319 | | [Avidity Partners Management LP](/funds/1791827.md) | 2026-06-30 | $205.1m | 2,104,184 | | Unchanged | | [Octagon Capital Advisors LP](/funds/1839435.md) | 2026-06-30 | $179.5m | 1,841,667 | | Reduced −105,000 | | [TCG Crossover Management, LLC](/funds/1839948.md) | 2026-06-30 | $163.4m | 1,676,624 | | Unchanged | | [FRED ALGER MANAGEMENT, LLC](/funds/3520.md) | 2026-06-30 | $127.0m | 1,302,493 | | Added +140,570 | ## Recent filings [All 650 filings](/companies/dnth/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-04 | 16:08 ET | [10-Q](/filings/0001690585-26-000034.md) | Quarterly report, period 2026-06-30 | 0001690585-26-000034 | | 2026-08-04 | 16:05 ET | [8-K](/filings/0001690585-26-000033.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001690585-26-000033 | | 2026-06-12 | 07:00 ET | [8-K](/filings/0001690585-26-000029.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001690585-26-000029 | | 2026-05-22 | 16:10 ET | [8-K](/filings/0001690585-26-000026.md) | 5.07 Shareholder vote results | 0001690585-26-000026 | | 2026-05-05 | 16:06 ET | [10-Q](/filings/0001690585-26-000022.md) | Quarterly report, period 2026-03-31 | 0001690585-26-000022 | | 2026-05-05 | 16:03 ET | [8-K](/filings/0001690585-26-000021.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001690585-26-000021 | | 2026-04-09 | 16:09 ET | [DEF 14A](/filings/0001690585-26-000012.md) | Proxy statement, period 2026-05-21 | 0001690585-26-000012 | | 2026-03-26 | 08:00 ET | [8-K](/filings/0001690585-26-000010.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001690585-26-000010 | | 2026-03-12 | 07:20 ET | [8-K](/filings/0001193125-26-103053.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-103053 | | 2026-03-09 | 07:21 ET | [10-K](/filings/0001690585-26-000006.md) | Annual report, period 2025-12-31 | 0001690585-26-000006 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001690585-26-000006.md), filed Mar 9, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1690585 - Tickers: DNTH - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.